Elanco posted Q2 sales of $1.24 billion, beating estimates and growing 5% YoY; adjusted EPS was $0.26, down 13% YoY. Pet Health revenue rose 11% to $643 million; Seresto and Advantage lines contributed $113 million and $147 million, respectively.

ELAN

<p>Elanco 公布第二季度销售额为 12.4 亿美元，超出预期，同比增长 5%；调整后的每股收益为 0.26 美元，同比下降 13%。宠物健康收入增长 11%，达到 6.43 亿美元；Seresto 和 Advantage 系列分别贡献了 1.13 亿美元和 1.47 亿美元</p>

为什么 Elanco Animal Health 的股票在周四大幅上涨？